Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Corvus Pharmaceuticals (NASDAQ:CRVS) from a sell rating to a hold rating in a research note published on Friday.

Corvus Pharmaceuticals Trading Down 0.6 %

Shares of CRVS opened at $5.10 on Friday. The stock has a market cap of $319.01 million, a P/E ratio of -9.81 and a beta of 1.13. Corvus Pharmaceuticals has a 1 year low of $1.05 and a 1 year high of $5.22. The stock’s 50-day moving average price is $3.35 and its two-hundred day moving average price is $2.40.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.05. During the same quarter in the prior year, the business posted ($0.14) EPS. As a group, equities analysts forecast that Corvus Pharmaceuticals will post -0.45 EPS for the current year.

Institutional Trading of Corvus Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Corvus Pharmaceuticals by 10.6% in the first quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock valued at $2,658,000 after acquiring an additional 142,724 shares during the period. Towerview LLC raised its position in shares of Corvus Pharmaceuticals by 4.6% during the second quarter. Towerview LLC now owns 400,000 shares of the company’s stock worth $728,000 after purchasing an additional 17,500 shares during the period. Samlyn Capital LLC lifted its holdings in shares of Corvus Pharmaceuticals by 160.7% during the 2nd quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after purchasing an additional 3,774,658 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Corvus Pharmaceuticals in the 2nd quarter valued at approximately $136,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Corvus Pharmaceuticals during the 2nd quarter worth approximately $44,000. Institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.